Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2012

Janku Filip, Wheler Jennifer J, Westin Shannon N, Moulder Stacy L, Naing Aung, Tsimberidou Apostolia M, Fu Siqing, Falchook Gerald S, Hong David S, Garrido-Laguna Ignacio, Luthra Rajyalakshmi, Lee J Jack, Lu Karen H, Kurzrock Razelle

Abstract excerpt

PURPOSE: Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance. PATIENTS AND METHODS: Tumors from patients with breast, cervical, endometrial, and ovarian cancer referred to the Clinical Center for Targeted Therapy (Phase I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genital Neoplasms, Female

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22271473
DOI: 10.1200/JCO.2011.36.1196
PMCID: PMC3295566

Genes

BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.PMID 22271473Read ↗

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Semantic proximity Read ↗

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Semantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.Semantic proximity Read ↗

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Semantic proximity Read ↗

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Semantic proximity Read ↗

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.